iSpecimen Earnings Call Transcripts
Fiscal Year 2026
-
Stockholders preliminarily approved the securities issuance, future-financing, asset-acquisition and adjournment proposals. The reverse-split vote remained open until Oct. 30, 2026, with the meeting adjourned only on that item.
-
The annual meeting was called to order but adjourned due to lack of quorum, with no business conducted. A new meeting date will be announced to allow more time for proxy submission and quorum attainment.
-
The annual meeting was called to order and properly noticed, but a quorum was not present, so no business or voting could proceed. The meeting was adjourned and will be reconvened at a later date in accordance with legal requirements.
-
The 2025 annual meeting was called to order and properly noticed, but a quorum was not present, so no business or voting could proceed. The meeting was adjourned to a later date to allow more time to obtain a quorum.
Fiscal Year 2024
-
Q2 2024 revenue rose 76% year-over-year to $2.9M, driven by operational improvements and the Next-Day Quote Program. Cash burn was reduced by 59% in the first half, and supplier consolidation improved capabilities. The company remains focused on cost control and securing additional funding.